Forest Enters Antibiotic Field Through Faropenem Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest will oversee U.S. sales and marketing efforts for the pending antibiotic Orapem under an agreement with Replidyne.